Breaking News: HUTCHMED’s ORPATHYS and TAGRISSO Combination Receives Priority Review Status for Lung Cancer Patients with MET Amplification in China!
Description:
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca.
Impact on Individuals:
For individuals battling lung cancer with MET amplification in China, the acceptance and priority review status of the ORPATHYS and TAGRISSO combination means that there is hope for a more effective treatment option. This combination of drugs offers a potential breakthrough in targeting specific mutations, providing a personalized approach to treatment that could improve outcomes and quality of life for patients.
Global Impact:
The acceptance and priority review of the ORPATHYS and TAGRISSO combination by the China NMPA not only signals a step forward in precision medicine for lung cancer treatment but also sets a precedent for other countries and healthcare systems worldwide. The recognition of the importance of targeted therapies and combination treatments could lead to advancements in cancer care on a global scale, impacting the way researchers and pharmaceutical companies approach treatment development.
Conclusion:
The prioritization and acceptance of the ORPATHYS and TAGRISSO combination for lung cancer patients with MET amplification in China marks a significant milestone in the fight against this disease. This event has the potential to change the landscape of cancer treatment, offering new hope and possibilities for patients not only in China but around the world. The collaboration between HUTCHMED and AstraZeneca showcases the power of innovation and partnership in driving progress in healthcare.
